Trials / Completed
CompletedNCT02361424
Pilot Study Assessing the Effects of PXT00864 in Patients With Mild Alzheimer Disease (AD)
First Single-blind Sequential Placebo-controlled Prospective Phase IIA Pilot Study Assessing the Effects of PXT00864 in Mild AD Patients
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 47 (actual)
- Sponsor
- Pharnext S.C.A. · Academic / Other
- Sex
- All
- Age
- 60 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to assess the safety and efficacy on cognitive impairment and functioning of several doses of PXT00864 (new fixed combination of acamprosate and baclofen at low dose) in patients with mild Alzheimer Disease.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | PXT00864 | PXT00864 is a fixed-dose combination of baclofen and acamprosate |
| DRUG | placebo |
Timeline
- Start date
- 2013-02-01
- Primary completion
- 2015-06-01
- Completion
- 2015-06-01
- First posted
- 2015-02-11
- Last updated
- 2016-02-15
Locations
1 site across 1 country: France
Source: ClinicalTrials.gov record NCT02361424. Inclusion in this directory is not an endorsement.